The mental load of being on an anti-obesity medication.

1. The mental load is not in the clinical scale

Anti-obesity medications (AOMs), and in particular GLP-1 receptor agonists like semaglutide and tirzepatide, have changed what is medically possible for adults living with obesity. What the clinical literature does not measure, because it is much harder to capture, is the daily mental work of being on this treatment.

That work is real. It does not show up in the BMI line, the side-effect grade, or the adherence chart. It shows up in the spaces between consultations: at family dinners, in pharmacy queues, in the silence after a colleague says "you look great, what is your secret?" It is the cost of carrying a medical condition that society still treats as a moral one. This article is about that cost, and about what helps reduce it.

2. The work of explaining your treatment

Few medical treatments are as exposed to public commentary as an AOM. Most people on antihypertensives, statins or antidepressants are not asked to justify them at family dinners. Most people on a GLP-1 are. Whether you choose to disclose your treatment or not, you carry a permanent decision: tell, do not tell, half-tell, change the subject.

The conversations are predictable, and they all extract energy:

• The well-meaning relative who has read an alarming headline and wants to "warn" you.
• The colleague who lost weight a decade ago "without medication" and offers their method.
• The friend who is happy for you, but in a way that implies the previous version of you was a problem to solve.
• The acquaintance who asks for your prescription, as if you were a personal pharmacy.

None of these are individually catastrophic. Cumulatively, they are exhausting. Naming this as a recurring social load, rather than as personal weakness, is the first step toward not being depleted by it.

3. The "shortcut" accusation, and where it comes from

A specific subset of the social load is the "shortcut" framing: the suggestion that an AOM is the easy way out, that "real" weight management requires willpower and suffering, and that medication is a form of cheating. This view has deep cultural roots, and they predate the existence of GLP-1 medication.

The international scientific community has spent the last decade trying to dismantle this framing. The World Obesity Federation has formally classified obesity as a chronic, relapsing, progressive disease,³ and the 2020 joint international consensus statement for ending stigma of obesity, published in Nature Medicine and signed by major medical and scientific societies, explicitly states that pharmacological and surgical treatments are legitimate medical options, and that the "personal responsibility" narrative is not supported by the evidence on appetite regulation, hormonal biology, and genetics.¹ Two decades of research from Puhl, Pearl and colleagues have documented how internalised weight stigma is associated with worse psychological distress, more disordered eating, and poorer cardiometabolic outcomes, independent of body mass.²⁶

Knowing this does not make the conversations disappear. It does change who is responsible for the discomfort. You are not.

4. The "who am I now" question

For some people, the most surprising part of an AOM is not the side effects, the cost, or the social load. It is the identity shift. Food, hunger, social rituals and self-image have been built over decades. When the appetite signal that organised the day quietly recedes, something else has to take its place.

Patients describe this in a few recurring ways:

• The body in the mirror does not match the internal map.
• Wardrobe, posture, photographs, the way strangers respond, all become unstable.
• Old strategies (the comfort meal, the planned binge, the "reward" food) lose their function. The replacement has not been built yet.
• For people who used food to manage anxiety, grief or loneliness, a different tool is needed, and that need can feel sharper before it feels lighter.

Naming this as identity work, not as a failure of gratitude, is important. It is also why structured medical and psychological support, recommended by the Endocrine Society 2015 clinical practice guideline as part of pharmacological obesity treatment, is part of the care, not an optional extra.⁵

5. The silence of the in-between months

Between consultations, it is quiet. AOM trajectories are slow. The next appointment is in three months. The medication keeps working in the background. The body keeps adjusting in small, mostly invisible increments. Family and colleagues have moved on from the topic. The novelty is gone.

This silence is when adherence is most fragile. Real-world data show that approximately half of adults starting a GLP-1 for obesity discontinue within the first year, and many of them never raise the topic with their physician, because the next appointment is far away and the reasons feel personal rather than clinical. We unpack this in our article on why half of GLP-1 patients stop in the first year.

A treatment as long-term as an AOM cannot live only inside the consultation. It needs an in-between layer: a place to log what you notice, a question line that does not require booking time, a community of people on the same trajectory. That gap is exactly what a medical companion app like Boli Care is designed to fill.

6. When the weight loss becomes visible to others

Around the third or fourth month, weight loss often becomes visible. This is meant to be a positive milestone. For many people, it is also a destabilising one.

The change in how strangers, colleagues and family treat you is often unsettling. Compliments arrive in volume. Some are warm, some are clumsy, some carry an implicit judgement of the previous version of you. Workwear no longer fits. Photographs from a year ago feel like they belong to someone else. Romantic partners, employers and friends respond differently, sometimes in ways that were not asked for. Practical advice on what to eat (and not count) is in our article on eating on GLP-1 without counting calories.

Two pieces of mental work matter here:

• Distinguish your relationship with your body (private, longitudinal) from other people's reactions to your body (public, episodic). The second one cannot be controlled.
• Anticipate the social load. A short, prepared sentence ("I am being treated for a chronic condition; thank you for asking") protects energy.

7. Emotional flatness, and naming it

A subset of patients on GLP-1 therapy report a flattening of emotional response: less anxiety but also less spontaneous joy, less reactivity in either direction. The mechanism is not fully understood, and the signal is not universal. It overlaps with the energy intake reduction itself, with sleep changes, and with the ordinary effects of chronic disease management.

Two things matter:

• This signal should be named, both with your physician and with people you trust. It is a real clinical observation, not an exaggeration.
• It should not be confused with depression, which has its own diagnostic criteria and may require its own intervention. Persistent low mood, loss of interest, or suicidal thoughts are red flags. Contact your physician.

International obesity-care frameworks, including NICE NG246 in the United Kingdom and the GCC-CSO/FORCE 2026 position paper in France, recommend ongoing psychosocial assessment as part of medical obesity care, not as an afterthought.⁴⁷ The Endocrine Society clinical practice guideline on the pharmacological management of obesity also recommends behavioural support alongside medication.⁵

8. What helps, and what does not

Three things, supported by behavioural literature and patient experience, reduce mental load on AOM:

• A peer community that knows the trajectory. Talking with people two months ahead of you normalises what is otherwise privatised. At Boli Care, that community is moderated by patient experts, with physician oversight on medical questions.
• Structured between-visit support. A simple, daily way to log what you notice, with the option to ask a clinical question. This compresses the silence between consultations and makes your next appointment more useful.
• Naming what is happening. The mental load, the identity shift, the emotional flatness, the social load: each has a name, and naming reduces its weight. Our short checklist for preparing your next AOM consultation covers what to bring up.

Three things do not help: toxic positivity ("just be grateful" is not an evidence-based intervention), weight-shaming wellness culture (which medicalises virtue and frames a medical treatment as cheating), and isolation. If you recognise yourself in several of these sections, you are not alone. The work you are doing is real medical work.

References

1. Rubino F, Puhl RM, Cummings DE, et al. Joint international consensus statement for ending stigma of obesity. Nature Medicine 2020;26(4):485-497. doi:10.1038/s41591-020-0803-x. PMID 32127716.
2. Puhl RM, Heuer CA. The stigma of obesity: a review and update. Obesity (Silver Spring) 2009;17(5):941-964. doi:10.1038/oby.2008.636. PMID 19165161.
3. Bray GA, Kim KK, Wilding JPH; World Obesity Federation. Obesity: a chronic relapsing progressive disease process. A position statement of the World Obesity Federation. Obesity Reviews 2017;18(7):715-723. doi:10.1111/obr.12551. PMID 28489290.
4. National Institute for Health and Care Excellence. Overweight and obesity management. Clinical guideline NG246. London: NICE. https://www.nice.org.uk/guidance/ng246.
5. Apovian CM, Aronne LJ, Bessesen DH, et al. Pharmacological management of obesity: an Endocrine Society clinical practice guideline. Journal of Clinical Endocrinology & Metabolism 2015;100(2):342-362. doi:10.1210/jc.2014-3415. PMID 25590212.
6. Pearl RL, Puhl RM. Weight bias internalization and health: a systematic review. Obesity Reviews 2018;19(8):1141-1163. doi:10.1111/obr.12701. PMID 29788533.
7. Aron-Wisnewsky J, Disse E, et al. Position paper of the Groupe de Coordination de la Coordination en Chirurgie de l'Obesite (GCC-CSO/FORCE) on the pharmacological treatment of obesity (TMO). Medecine des Maladies Metaboliques 2025/2026. doi:10.1016/j.mmm.2025.10.003.